Aftovaxpur DOE

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

Hámarks þrjú eftirfarandi hreinsað, óvirkur gin-og klaufaveiki veira stofnar: O1 Verkir stærri 6 PD50*; O1 BFS STÆRRI 6 PD50*; O Taívan 3/97 stærri 6 PD50*; A22 Írak stærri 6 PD50*; A24 Sao stærri 6 PD50*; Kalkúnn 14/98 stærri 6 PD50*; Asíu 1 Shamir stærri 6 PD50*; SAT2 Sádi-Arabíu sem stóð 6 PD50*; * PD50 – 50% verndandi skammt í nautgripum eins og lýst er í Doktor Evra. fræðilega 0063.

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI02AA04

INN (International Name):

inactivated vaccine against foot-and-mouth disease

Therapeutic group:

Pigs; Cattle; Sheep

Therapeutic area:

Ónæmisfræðilegar upplýsingar

Therapeutic indications:

Virk ónæmisaðgerð nautgripa, sauðfjár og svína frá 2 vikna aldri gegn gin- og klaufaveiki til að draga úr klínískum einkennum.

Product summary:

Revision: 8

Authorization status:

Aftakað

Authorization date:

2013-07-15

Patient Information leaflet

                                17
B. FYLGISEÐILL
Lyfið er ekki lengur með markaðsleyfi
18
FYLGISEÐILL:
AFTOVAXPUR DOE STUNGULYF, FLEYTI HANDA NAUTGRIPUM, SAUÐFÉ OG SVÍNUM
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
ÞÝSKALAND
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
69800 Saint Priest
Frakkland
2.
HEITI DÝRALYFS
AFTOVAXPUR DOE stungulyf, fleyti handa nautgripum, sauðfé og svínum
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hver 2 ml skammtur af fleyti inniheldur:
VIRK INNIHALDSEFNI:
Hreinsaðir og óvirkjaðir gin- og klaufaveiki veiru mótefnavakar,
a.m.k. 6 PD
50
* í stofni.
*PD
50
– 50% verndandi skammtur fyrir nautgripi eins og er lýst í
gæðalýsingu 0063 í Ph. Eur.
Fjöldi og tegund stofna sem verða í lokaafurðinni verður
aðlagað að faraldsfræðilegum aðstæðum á
þeim tíma sem lyfið er framleitt og mun koma fram á umbúðunum.
ÓNÆMISGLÆÐIR:
Paraffínolía 537 mg.
Hvítt fleyti eftir að hafa verið hrist.
4.
ÁBENDING(AR)
Virk ónæmisaðgerð á nautgripum, sauðfé og svínum frá 2 vikna
aldri gegn gin- og klaufaveiki til þess
að draga úr klínískum einkennum.
Ónæmi myndast:
Nautgripir og sauðfé: 7 dögum eftir bólusetningu.
Svín: 4 vikum eftir bólusetningu.
Ónæmi endist: Bólusetning nautgripa, sauðfjár og svína hvatar
myndun hlutleysandi mótefna sem
endist í a.m.k. 6 mánuði. Hjá nautgripum var mælt magn mótefna
yfir því magni sem sýnt hefur verið
að sé verndandi.
Lyfið er ekki lengur með markaðsleyfi
19
5.
FRÁBENDINGAR
Engar.
6.
AUKAVERKANIR
Bólga (þvermál allt að 12 cm hjá jórturdýrum og 4 cm hjá
grísum) er mjög algeng hjá flestum dýrum
eftir gjöf bóluefnis. Yfirleitt ganga þessi staðbundnu viðbrögð
til baka á 4 vikum eftir bólusetningu, en
geta verið þrálát hjá örfáum dýrum.
Örlítil 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
Lyfið er ekki lengur með markaðsleyfi
2
1.
HEITI DÝRALYFS
AFTOVAXPUR DOE stungulyf, fleyti handa nautgripum, sauðfé og svínum
2.
INNIHALDSLÝSING
Hver 2 ml skammtur af fleyti inniheldur:
VIRK INNIHALDSEFNI:
Að hámarki þrír af eftirfarandi hreinsuðum og óvirkjuðum gin-
og klaufaveiki veirustofnum:
O1 Manisa
.................................................................................................................................
≥ 6 PD
50
*
O1 BFS
.......................................................................................................................................
≥ 6 PD
50
*
O Taiwan 3/97
............................................................................................................................
≥ 6 PD
50
*
A22 Iraq
......................................................................................................................................
≥ 6 PD
50
*
A24 Cruzeiro
..............................................................................................................................
≥ 6 PD
50
*
A Turkey 14/98
..........................................................................................................................
≥ 6 PD
50
*
Asia 1 Shamir
.............................................................................................................................
≥ 6 PD
50
*
SAT2 Saudi Arabia
....................................................................................................................
≥ 6 PD
50
*
* PD
50
–
50% verndandi skammtur fyrir nautgripi eins og er lýst í
gæðalýsingu 0063 í Ph. Eur.
Fjöldi og gerð veirustofna sem verður í endanlegu lyfi verður
aðlöguð að faraldsfræðilegu ástandi á
þeim tíma sem samsetning endanlegs lyfs er ákveðin og mun koma
fram á merkingu umbúða.
ÓNÆMISGLÆÐIR:
Paraffínolía
.......................................................................................................................
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-07-2023
Public Assessment Report Public Assessment Report Bulgarian 13-06-2016
Patient Information leaflet Patient Information leaflet Spanish 04-07-2023
Public Assessment Report Public Assessment Report Spanish 04-07-2023
Patient Information leaflet Patient Information leaflet Czech 04-07-2023
Public Assessment Report Public Assessment Report Czech 13-06-2016
Patient Information leaflet Patient Information leaflet Danish 04-07-2023
Public Assessment Report Public Assessment Report Danish 13-06-2016
Patient Information leaflet Patient Information leaflet German 04-07-2023
Public Assessment Report Public Assessment Report German 13-06-2016
Patient Information leaflet Patient Information leaflet Estonian 04-07-2023
Public Assessment Report Public Assessment Report Estonian 04-07-2023
Patient Information leaflet Patient Information leaflet Greek 04-07-2023
Public Assessment Report Public Assessment Report Greek 13-06-2016
Patient Information leaflet Patient Information leaflet English 04-07-2023
Public Assessment Report Public Assessment Report English 04-07-2023
Patient Information leaflet Patient Information leaflet French 04-07-2023
Public Assessment Report Public Assessment Report French 04-07-2023
Patient Information leaflet Patient Information leaflet Italian 04-07-2023
Public Assessment Report Public Assessment Report Italian 04-07-2023
Patient Information leaflet Patient Information leaflet Latvian 04-07-2023
Public Assessment Report Public Assessment Report Latvian 04-07-2023
Patient Information leaflet Patient Information leaflet Lithuanian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-07-2023
Public Assessment Report Public Assessment Report Lithuanian 04-07-2023
Patient Information leaflet Patient Information leaflet Hungarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-07-2023
Public Assessment Report Public Assessment Report Hungarian 04-07-2023
Patient Information leaflet Patient Information leaflet Maltese 04-07-2023
Public Assessment Report Public Assessment Report Maltese 04-07-2023
Patient Information leaflet Patient Information leaflet Dutch 04-07-2023
Public Assessment Report Public Assessment Report Dutch 04-07-2023
Patient Information leaflet Patient Information leaflet Polish 04-07-2023
Public Assessment Report Public Assessment Report Polish 04-07-2023
Patient Information leaflet Patient Information leaflet Portuguese 04-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-07-2023
Public Assessment Report Public Assessment Report Portuguese 04-07-2023
Patient Information leaflet Patient Information leaflet Romanian 04-07-2023
Public Assessment Report Public Assessment Report Romanian 04-07-2023
Patient Information leaflet Patient Information leaflet Slovak 04-07-2023
Public Assessment Report Public Assessment Report Slovak 04-07-2023
Patient Information leaflet Patient Information leaflet Slovenian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 04-07-2023
Public Assessment Report Public Assessment Report Slovenian 04-07-2023
Patient Information leaflet Patient Information leaflet Finnish 04-07-2023
Public Assessment Report Public Assessment Report Finnish 04-07-2023
Patient Information leaflet Patient Information leaflet Swedish 04-07-2023
Public Assessment Report Public Assessment Report Swedish 04-07-2023
Patient Information leaflet Patient Information leaflet Norwegian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-07-2023
Patient Information leaflet Patient Information leaflet Croatian 04-07-2023
Public Assessment Report Public Assessment Report Croatian 04-07-2023

View documents history